Trials / Terminated
TerminatedNCT01065077
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cinaciguat (BAY58-2667) | Infusion of 150 µg/h during 48h |
| DRUG | Cinaciguat (BAY58-2667) | Infusion of 100 µg/h during 48h |
| DRUG | Cinaciguat (BAY58-2667) | Infusion of 50 µg/h during 48h |
| DRUG | Placebo | Infusion of placebo during 48h |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-01-01
- Completion
- 2011-02-01
- First posted
- 2010-02-09
- Last updated
- 2015-10-08
Locations
59 sites across 17 countries: United States, Austria, Croatia, Finland, Germany, Israel, Italy, Japan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Sweden, Switzerland, Thailand
Source: ClinicalTrials.gov record NCT01065077. Inclusion in this directory is not an endorsement.